Agios Pharmaceuticals Inc. announced its acquisition of Alnylam Pharmaceuticals, Inc.‘s siRNA blood disease program targeting TMPRSS6, a gene that makes protein. According to data captured in the LevinPro HC database, this transaction marks the 105th Biotechnology acquisition in 2023.
Alnylam is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002. According to its most recent financial report, the company achieved net product revenues of $894 million during FY 2022.
Agios is the pioneering leader in pyruvate kinase (PK) activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the United States, Agios markets a first-in-class PK activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. The company reported $14.24 million in revenue for the full year ending on December 31, 2022.
Under the terms of the agreement, Agios will make an upfront payment of $17.5 million to Alnylam for an exclusive global license to the TMPRSS6 siRNA program. In addition, Alnylam is eligible to receive up to $130 million in potential development and regulatory milestone payments, in addition to sales milestones and tiered royalties.
This agreement combines Agios’ deep scientific expertise and capabilities in rare hematologic diseases with Alnylam’s industry-leading siRNA platform and strong track record of success.
